ROSELAND, N.J., May 27, 2022 (GLOBE NEWSWIRE) -- Milestone Scientific Inc. (NYSE:MLSS), a leading developer of computerized drug delivery instruments, that provide painless and precise injections, today reported that it has commenced sales of its CompuFlo® Epidural instrument disposables at a leading veterinary and academic institution following a successful research study and evaluation. The veterinary institution has initially begun using the CompuFlo Epidural instrument for maxillary nerve block procedures in horses with plans to expand into epidural procedures.
The CompuFlo Epidural instrument has been evaluated in multiple studies in veterinary medicine. A published study in June 2020, which focused on the maxillary nerve block in horses, concluded that use of the CompuFlo Epidural instrument would not only serve as a valuable teaching tool, but also increase the success rate of less experienced equine practitioners. The study further noted that the CompuFlo/DPS® technology provided beneficial guidance to the operator when inserting the needle to its intended target location, thereby increasing the overall success rate when compared to using solely anatomic surface landmarks for guidance.
Dr. Bernd Driessen, an equine anesthesiologist that participated in earlier clinical studies of the instrument, commented, “I am excited to see commercial uptake of the CompuFlo Epidural instrument in clinical practice, as well as in the classroom to educate the next generation of veterinarians. The CompuFlo Epidural instrument can provide fellow veterinarians and students greater accuracy through real-time verification of needle location when performing a maxillary nerve block.”
Arjan Haverhals, CEO of Milestone Scientific, commented, “This institution’s team continually leads the way in advancements in veterinary medicine, and we are honored to provide them with our proven technology. Milestone is continually evaluating additional channels to commercialize our technology, including new medical indications. Veterinary medicine is just one example of another market that will benefit from our CompluFlo Epidural instrument. We believe the extensive prior studies, spanning epidural, peripheral nerve block, intra-articular, and veterinary use cases reinforce the enhanced safety, improved outcomes, economic benefits and broad market potential of our instrument.”
About Milestone Scientific Inc. Milestone Scientific Inc. (MLSS), a technology focused medical research and development company that patents, designs and develops innovative injection technologies and instruments for medical, dental and cosmetic applications. Milestone Scientific’s computer-controlled systems are designed to make injections precise, efficient and increase the overall patient comfort and safety. Their proprietary DPS Dynamic Pressure Sensing Technology® instruments is the platform to advance the development of next-generation devices, regulating flow rate and monitoring pressure from the tip of the needle, through platform extensions of subcutaneous drug delivery, including local anesthetic. To learn more, view the MLSS brand video or visit milestonescientific.com.
Safe Harbor Statement This press release contains forward-looking statements regarding the timing and financial impact of Milestone's ability to implement its business plan, expected revenues, timing of regulatory approvals and future success. These statements involve a number of risks and uncertainties and are based on assumptions involving judgments with respect to future economic, competitive and market conditions, future business decisions and regulatory developments, all of which are difficult or impossible to predict accurately and many of which are beyond Milestone's control. Some of the important factors that could cause actual results to differ materially from those indicated by the forward-looking statements are general economic conditions, failure to achieve expected revenue growth, changes in our operating expenses, adverse patent rulings, FDA or legal developments, competitive pressures, changes in customer and market requirements and standards, and the risk factors detailed from time to time in Milestone's periodic filings with the Securities and Exchange Commission, including without limitation, Milestone's Annual Report for the year ended December 31, 2020. The forward-looking statements in this press release are based upon management's reasonable belief as of the date hereof. Milestone undertakes no obligation to revise or update publicly any forward-looking statements for any reason.
Contact: David Waldman or Natalya Rudman Crescendo Communications, LLC Email: mlss@crescendo-ir.com Tel: 212-671-1020
Northwestern UniversityFun fact: Your heart doesn’t need a brain, or a body for that matter, to beat. That’s because it has its own electrical system independent of your nervous system. However, the heart’s beating can go haywire in certain medical conditions.This is where pacemakers come in. These devices are typically hooked up to the heart and resets it using electrical signals if it ever beats too fast or too slow. Some people need to be on pacemakers for life, while others only need it for
In the second part of his question-and-answer session, WSP’s Earth and Environment leader looks at remediation regulations, wind and solar opportunities and more.
The pharmaceutical company’s shares have been a bright spot in a tough market—and the move higher may just be getting started.
(Bloomberg) -- Rising helium costs, missing auto parts, and shipping delays are spurring a new wave of financial trouble for companies already saddled with debt amid broader concern that the US economy is on the brink of a downturn.Most Read from BloombergStocks Buoyed by Retail Earnings in Risk-On Day: Markets WrapRare Ship-to-Ship Transfers Keep Oil Moving From Russia to ChinaTop Gun: Maverick's F-18 Flights Cost New Tom Cruise Film $11,374 an HourUkraine Latest: Putin Ties Grain Exports to Dr
The stock market selloff has made many stocks look cheap—but smart investors need to be selective. Here are six high-quality companies that trade at reasonable valuations.
Do you need free transportation? Do you need advertising for your brand? GEST Carts Chicago has got you covered! Here's what co-owner Tiffany Shepard has to say.
Ankiti Bose cofounded the Singapore-based startup Zilingo to connect small businesses, and it scaled up rapidly. An ongoing probe over financial irregularities led to her suspension and termination.
The cloud computing company now expects full-year revenue of $1.54 billion to $1.56 billion, down from the previous estimate of $1.63 billion.
Apyx Medical Corporation (NASDAQ: APYX) has FDA received 510(k) clearance for the use of the Renuvion Dermal Handpiece for specific dermal resurfacing procedures. The Renuvion Dermal Handpiece is indicated for dermatological procedures to treat moderate to severe wrinkles and rhytides, limited to patients with Fitzpatrick skin types I, II, or III. The company expects to begin a limited launch of Renuvion for this indication in Q3 of 2022, to enter full commercialization by the end of 2022. "We a
Asian shares gained Friday as investors cheered a strong set of earnings from retailers that has sent U.S. shares higher.
A strong dollar typically weighs on oil prices because it makes the commodity more expensive for holders of other currencies, potentially hurting demand for crude. MUFG expects the divergence between the dollar and broader commodities besides oil to continue.
CEO Scott Kavanaugh said it took longer than he had expected to get the de novo branch in Plano up and running, but he is optimistic about deposit growth.
Gap Inc slashed its annual results forecast on Thursday, sending shares 13% lower after hours as the clothing retailer blamed poor fashion choices at its Old Navy line and weak demand in the face of decades-high inflation. The Banana Republic parent also posted a much wider-than-expected quarterly loss, slammed by surging costs of air freight and deeper discounts. The dismal outlook echoes peers American Eagle Outfitters and Abercrombie & Fitch Co as rising prices of essentials like food force consumers to limit discretionary spending.
(Bloomberg) -- Lenovo Group Ltd.’s profit beat market estimates after the world’s biggest personal computer maker widened its lead over longtime rival HP Inc.Most Read from BloombergFord Beats Tesla to the Punch With First Electric F-150 DeliveryRussian Wins in Eastern Ukraine Spark Debate Over Course of WarStocks Notch Their Best Week Since November 2020: Markets WrapZilingo’s Fired CEO Responds to Questions of Mystery PaymentsUkraine Latest: US Slams Putin’s Food-for-Sanctions Relief PlanNet i
Some investors turned to nonfungible tokens in search of a haven among digital assets in the first quarter. However, the bets soon turned sour.
Rivian Automotive is shaking up its production plans and management. “We have updated our product roadmap to drive focus and are making organizational changes to ensure rapid progress and keep pace with our projected growth,” said CEO R.J. Scaringe in an internal email quoted earlier by Bloomberg and confirmed by the company. Changes to the product roadmap—management’s plan for what vehicles to produce, and when—could mean Rivian could move forward the first deliveries of its sport-utility vehicle, the R1S, now due to reach customers later this year.
CEO media pay hits median of $14.5 million as the economy rebounded in 2021. Much of the compensation is from soaring stock price gains.
Even when regular workers win their biggest raises in decades, they look minuscule compared with what CEOs are getting.
That is still more than three times the Fed's 2% target. The decline in core inflation is particularly good news for the central bank, along with fresh evidence that household spending continues to grow despite still fast-rising prices. "While inflation levels in the 4% range are still too high for the Fed, we are seeing movement in the right direction," Nationwide Economist Dan Hadden wrote in a note.
A growth-stock investor makes the case for a return to form in small-cap growth stocks. Plus, Broadcom and the chip shortage, Snap and internet advertising, and Thomas Peterffy on zero-commission trading.